According to the published joint guideline recommendations in 2007 of the College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO), it has been a routine pathological diagnosis to detect HER2 status in breast cancer all over the world [3, 4], not only for the prognostic evaluation for breast cancer patients but also a key element of the adjuvant therapy for HER2-positive patients. This evidence concerns the gene ERBB2 and breast cancer.